Oliver P. Peoples, Ph.D. was named President and Chief Executive Officer of Metabolix in October 2016 in conjunction with the transition to Yield10 Bioscience as the company's core business. Dr. Peoples was a co-founder of Metabolix and served as our Chief Scientific Officer from January 2000 until October 2016, and was previously our Vice President of Research and Development. Dr. Peoples has served as a director since June 1992. Prior to founding Metabolix, Dr. Peoples was a research scientist with the Department of Biology at the Massachusetts Institute of Technology where he emerged as a pioneer of the new field of metabolic pathway engineering and its applications in industrial biotechnology. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce Mirel biopolymers. Dr. Peoples has published numerous peer-reviewed academic papers and is an inventor of over 90 patents and patent applications worldwide. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.
Robert L. Van Nostrand is a consultant who has served as Chairman since October 2013 and as a Director since October 2006. From January 2010 to July 2010, he was the Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc. From July 2007 until September 2008, Mr. Van Nostrand served as the Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc. Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. from 1986 to 2007, serving as Senior Vice President and Chief Compliance Officer from May 2005 until July 2007, and as the Vice President and Chief Financial Officer from 1996 through 2005. Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. (currently Deloitte and Touche). Mr. Van Nostrand serves on the board of directors and is chairman of the audit committee and a member of the compensation committee of Achillion Pharmaceuticals, Inc. since 2007, serves on the board of directors and is chairman of the audit committee of Intra-Cellular Therapies, Inc. since January 2014, serves on the board of directors of the Biomedical Research Alliance of New York (BRANY) since 2011, and served on the board of directors and as chair of the audit committee of Apex Bioventures, Inc. from 2006 to 2009. Mr. Van Nostrand received a B.S. in Accounting from Long Island University, New York, completed advanced management studies at the Wharton School, and he is a Certified Public Accountant.
Sherri M. Brown, Ph.D. became a Director of the company in February 2020. Dr. Brown previously served as a Special Commercial and Technical Advisor to the company since December 2018. As of 2017, Dr. Brown has served as the managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in several leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean, and corn at Monsanto Company for 28 years. She served as the Vice President of Science Strategy at Monsanto from 2014 to 2017 and as a member of the Monsanto Leadership Council. Prior to that, she was the Vice President of Global Commercial Technology/Product Development from 2008 to 2014 where she was responsible for evaluating and launching the seed and trait pipeline, including eight new biotech traits. In addition, she was Vice President of Technology and Global Corn Business (1999-2004) and Vice President of Technology and Oilseeds Business (1998-1999). Dr. Brown earned a Ph.D. at Indiana University, Bloomington, IN with a major in Genetics/Molecular, Cellular, and Developmental Biology. She earned a B.S. at Hope College, Holland, MI with a double major in Biology and Chemistry.
Richard W. Hamilton, Ph.D. became a Director of the company in March 2017. From 1998 to 2002, he served as Chief Financial Officer of Ceres, Inc., an agricultural biotechnology company that developed and marketed seeds and traits to produce crops for animal feed, sugar, and other markets. From 2002 to 2016, Dr. Hamilton became a member of the board of directors at Ceres. In 2016, Ceres was acquired by Land O'Lakes. In addition to his leadership role there, Dr. Hamilton has sat on the Keck Graduate Institute Advisory Council and he was a founding member of the Council for Sustainable Biomass Production. He has served on the U.S. Department of Energy's Biomass Research and Development Technical Advisory Committee and has been active in the Biotechnology Industry Organization where he has served as Vice Chairman of the organization, chaired its Food and Agriculture Governing Board, and served in other leadership roles. From 1996 to 1998, Dr. Hamilton was a Principal at Oxford Bioscience Partners, one of the leading investors in the genomics field, and a founder of Ceres. He was an Associate at Boston-based MVP Ventures from 1993 to 1996. From 1990 to 1992, he was a Howard Hughes Medical Institute Research Fellow at Harvard Medical School. Dr. Hamilton holds a Ph.D. in molecular biology from Vanderbilt University and a B.S. in biology from St. Lawrence University.
Anthony J. Sinskey, Sc.D., a co-founder of Metabolix, has served as a director since June 1992. From 1968 to the present, Dr. Sinskey has been on the faculty of MIT. Currently at MIT, he serves as Professor of Microbiology in the Department of Biology and Professor of Health Sciences and Technology in the Harvard-MIT Health Sciences and Technology Program, Engineering Systems Division, as well as Faculty Director of the Center for Biomedical Innovation. Dr. Sinskey serves on the board of directors of Tepha, Inc. He received a B.S. from the University of Illinois and an Sc.D. from MIT.